Pharmacokinetic and pharmacodynamic variability: A daunting challenge in drug therapy

被引:52
作者
Lin, Jiunn H. [1 ]
机构
[1] Merck Sharp & Dohme Ltd, Res Labs, Dept Preclin Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.2174/138920007779816002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Patients vary considerably in their response to drug therapy. A drug that proves to be pharmacologically effective in some patients at a given dose may be ineffective or even toxic in others. The interindividual variability in drug response represents a major challenge in drug therapy, particularly for drugs with narrow therapeutic index. The intensity and duration of a drug action are determined not only by pharmacokinetic processes, but also by pharmacodynamic processes. Therefore, the variability in drug response is a result of the variability in either pharmacokinetic or pharmacodynamic processes, or a combination of both. The purpose of this paper is to review the sources that contribute to pharmacokinetic and pharmacodynamic variability. Although the main focus will be on the genetic variability, the impact of environmental factors on drug response will also be discussed. Finally, the application and limitation of the concept of personalized medicine will be briefly discussed.
引用
收藏
页码:109 / 136
页数:28
相关论文
共 328 条
[31]   Ethnic and genetic determinants of omeprazole disposition and effect [J].
Caraco, Y ;
Lagerstrom, PO ;
Wood, AJJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :157-167
[32]  
Caraco Y, 2001, CLIN PHARMACOL THER, V69, pP63
[33]  
Cardot JM, 1998, BIOPHARM DRUG DISPOS, V19, P259, DOI 10.1002/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO
[34]  
2-V
[35]   Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication [J].
Cascorbi, I .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 :17-22
[36]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[37]   Prolonged succinyleholine-induced apnoea associated with cholinesterase silent plasma variant [J].
Ceppa, F ;
Kenane, N ;
Chellak, S ;
Bigaillon, C ;
Burnat, P .
ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 2005, 24 (04) :425-427
[38]   Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium [J].
Cerf, C ;
Mesguish, M ;
Gabriel, I ;
Amselem, S ;
Duvaldestin, P .
ANESTHESIA AND ANALGESIA, 2002, 94 (02) :461-466
[39]  
CHAUDHURI TK, 1990, AM J GASTROENTEROL, V85, P223
[40]   The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry [J].
Chen, SQ ;
Chou, WH ;
Blouin, RA ;
Mao, ZP ;
Humphries, LL ;
Meek, C ;
Neill, JR ;
Martin, WL ;
Hays, LR ;
Wedlund, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (05) :522-534